OS Therapies Incorporated (NYSE American: OSTX) announced the appointment of Frank Knuettel II as Chief Financial Officer and Kerry Clem as Chief Commercial Officer, effective September 29, 2026. The appointments are part of the company's strategy to prepare for the commercial launch of its lead product candidate, Herlystic (OST-HER2).

Frank Knuettel II, 60, will serve as CFO. He brings over three decades of executive leadership experience in the technology and life sciences sectors. Prior to joining OS Therapies, Mr. Knuettel served as CFO and CEO of Channel Therapeutics Corporation (now Pelthos Therapeutics Inc.) and previously held the CEO role at Unrivaled Brands, Inc. He has raised over $500 million in capital and managed more than 15 mergers and acquisitions. Mr. Knuettel holds a B.A. in Economics from Tufts University and an M.B.A. from The Wharton School.

In connection with his appointment, Mr. Knuettel entered into a three-year employment agreement with a base salary of $300,000, which increases to $360,000 following a material transaction exceeding $10 million. He is also eligible for equity awards, including an initial grant of 750,000 stock options and 250,000 restricted stock units (RSUs), as well as performance-based grants tied to specific milestones such as capital raises or licensing deals exceeding $10 million.

Kerry Clem, 57, will serve as Chief Commercial Officer. He previously served as CEO and CCO of Solaxa Inc. and held senior commercial leadership roles at Acorda Therapeutics. Mr. Clem has over 25 years of experience in sales and marketing within the biotechnology and specialty therapeutics sectors. He holds a B.S. degree from Florida State University.

Mr. Clem’s employment agreement includes a base salary of $300,000 and an initial equity grant of 700,000 stock options and 200,000 RSUs. Both executives are subject to severance benefits and standard confidentiality and non-competition agreements.

The company also disclosed that it has entered into agreements with major vendors to delay accounts payable due dates until the second quarter of 2027. Additionally, OS Therapies has received over $3 million in non-dilutive capital from Value Added Tax refunds and accrued over $7 million in R&D tax credits, which will fund research and development activities for Herlystic.